Preclinical studies have also supported the stratification of PTEN-deficient prostate cancer patients for AKT inhibitor treatment [206,207,208,209,210], yet activation of potential therapeutic resistance pathways has been identified (discussed below, [180,207,211,212]). The gene discussed is AKT1; the disease is prostate carcinoma.